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with brine (20 mL), dried over Na 2 SO 4 , and concentrated to give an aldehyde, which was used for next step without further purification. To a suspension of Ph 3 PCH 3 Br (8.0 g, 22.5 mmol) in THF (45 mL) was added t-BuOK (2.52 g, 22.5 mmol) slowly at 0 °C . After stirred for 1h at room temperature, the reaction mixture was cooled to 0 °C and a solution of the crude aldehyde in THF (9 mL) was added. The reaction mixture was stirred overnight and quenched by adding water (25 mL). The aqueous layer was extracted with EtOAc (3 x 20 mL) and the combined organic phases were washed with brine (20 mL), dried over Na 2 SO 4 , concentrated, and purified with column chromatography (silica gel, EtOAc/Hexanes 1:6) to give 9 as a colorless oil (1.77 g, 87%) . 1 Compound 10. A solution of 9 (1.1 g, 4.91 mmol) in CH 2 Cl 2 (100 mL) was degassed, followed by addition of 2 nd generation Grubbs' catalyst (172 mg, 5 mmol%). The reaction mixture was stirred overnight at room temperature and concentrated under reduced pressure to give a brown dark residue, which was dissolved in CH 2 Cl 2 (20 mL). Dess-Martin periodinane (DMP, 3.11 g, 7. 34 mmol) and NaHCO 3 (619 mg, 7.34 mmol) were added into the solution. After 2 h, the reaction was quenched by adding saturated Na 2 S 2 O 3 (30 mL) and ether (100 mL) and stirred for 30 min. The separate organic layer was dried over Na 2 SO 4 , concentrated and the residue purified with column chromatography (silica gel, EtOAc/Hexanes 1:8) to give 10 as a colorless oil (821 mg, 86% (1.45 mL) in THF (5 mL) was added slowly. The reaction was further stirred at -78 °C for 5 h, allowed to warm to 0 °C and quenched with saturated NH 4 Cl (10 mL). The aqueous layer was extracted with S5 EtOAc (3 x 10 mL) and the combined organic phases were washed with brine (10 mL), dried over 
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temperature over 1 h and concentrated to give a syrup, which was dissolved in MeOH (8 mL). NaBH 4 (148 mg, 4 mmol) was added into the solution at 0 °C and stirred for 1 h before adding water. The product was extracted with EtOAc (3 x 10 mL) and the combined organic phases were washed with brine (10 mL), dried over Na 2 SO 4 , filtered and concentrated under reduced pressure to give a colorless oil. It was dissolved in CH 2 Cl 2 (4.5 mL) at 0 °C, and trifluoroacetic acid (TFA, 0.5 mL) was added dropwise. After stirring for 2 h at room temperature, the solvent was removed under reduced pressure and CH 2 Cl 2 (10 mL) was added. This step was repeated for 3 times and the resulting residue was purified with column chromatography (silica gel, 5% methanol in ethyl acetate) to give 13 as a white solid (635mg, 99% After stirring overnight at room temperature, the solvent was evaporated and the resulting residue was purified with column chromatography (silica gel, EtOAc) to give the product (698 mg, 92%) as a white foam, which was refluxed with hydrazine monohydrate (480 mg, 9.6 mmol) in EtOH (15 mL) for 2 h. Upon cooling and filtering off an insoluble material, the filtrate was concentrated under reduced pressure and purified with column chromatography (silica gel, EtOAc:methanol (9:1) containing 1% triethylamine) to
give a primary amine as a syrup (500 mg, 99%). To a solution of the product (690 mg, 2.0 mmol) in MeOH (20 mL) were added HOAc (1.16 mL), acetone (2.0 mL) and NaBCNH3 (730 mg, 10.0 mmol) at 0 °C. After stirring overnight, the solvent was removed under reduced pressure. Water (10 mL) was added and the product was extracted with EtOAc (6 x 20 mL). The combined organic phases were dried over Na2SO4, concentrated under reduced pressure, and purified with column chromatography (silica gel, EtOAc:methanol (9:1) containing 1% triethylamine) to give 14 as a white oil (733 mg, 95% 
1-(3-((((1R,2R,3S,4R)-4-adenosyl-2,3-dihydroxycyclopentyl)methyl)(isopropyl)amino)propyl)-3-(4-(tert-butyl)phenyl)urea (6).
Using steps xii and xiii (Scheme 1) described above, compound 15 (700 mg, 1.6 mmol) was subjected to a Mitsunobu reaction with phthalimide, followed by treatment with hydrazine, to give compound 16 as a white foam (640 mg, 91%). To a solution of 16 (222 mg, 0.5 mmol) in CH 2 Cl 2 (4 mL), triethylamine (77 µL, 0.55 mmol) and 4-tert-butylphenylisocyante (200 µL, 0.5 mmol) were added at 0 °C. The reaction mixture was warmed to room temperature and stirred for 1h.
Upon removal of the solvent, the residue was purified with column chromatography (silica gel, EtOAc:methanol 20:1) to give the cyclohexanone protected 6 (294 mg, 95%) as a white solid, which was treated with HCl (1.0 mL, 4 M in dioxane) in MeOH (3.0 mL) for 12 h. After removal of the solvent, the solid was washed with ethyl acetate (3 x 3 mL) to give compound 6 as a white powder (265 mg, 92%). 
1-(3-((((3R,4S,5R)-3-adenosyl-4,5-dihydroxycyclopent-1-en-1-yl)methyl)(isopropyl)amino)propyl)-

3-(4-(tert-butyl)phenyl)urea (7).
Using steps xii and xviii (Scheme 1) described in the making of 6, compound 23 (487.0 mg, 1.2 mmol) was converted to give compound 7 as a white powder (440 mg, 60% ((((1S,2R,3S,4R )-4-adenosyl-2,3-dihydroxycyclopentyl)methyl)(isopropyl)amino)propyl)-3-(4-(tert-butyl)phenyl)urea (epi-6). To a solution of compound 7 (35 mg, 0.057 mmol) in MeOH (4 mL) was added 10% Pd/C (5 mg). The reaction mixture was stirred at room temperature with a hydrogen balloon for 2 h. The reaction mixture was filtered through a 0.2 µm syringe filer and washed with methanol. The filtrate was concentrated under reduced pressure to afford epi-6 as a white solid (32 mg, 91% Enzyme inhibition. Expression, purification and inhibition of recombinant human DOT1L (catalytic domain 1 -472) were performed according to our previous published methods. 1, 2 In brief, compounds with concentrations ranging from 1 nM to 100 μM were incubated with DOT1L (100 nM), 1.5 μM oligo-nucleosome in 20 μL of 20 mM Tris buffer (containing 1 mM EDTA, 0.5 mM DTT and 50 μg/mL BSA, pH = 8.0) for 10 min. 0.76 μM (= K m ) of 3 H-SAM (10 Ci/mM; Perkin-Elmer) was added to initiate the reaction. After 30 min at 30 ºC, the reaction was stopped by adding SAH (100 μM). 15 μL of reaction mixture was transferred to P81 filter paper (Whatman) that binds histone H3 protein, washed 3x with 50 mM NaHCO 3 , dried, and placed into a scintillation vial containing scintillation cocktail (2 mL), which was measured with a Beckman LS-6500 scintillation counter. K i values were calculated using the Morrison tight binding model fitting or standard sigmoidal dose response curve fitting (for less potent inhibitors) in Prism 5.0. Enzyme inhibition assays for PRMT1, CARM1 and SUV39H1 were performed using our previous methods.
1,2
Western blot. MV4-11 cells in the exponential growth phase were incubated in the presence of increasing concentrations of a compounds (0.025 -15.625 µM). Cells (2×10 6 ) were harvested at day 4 and histones were extracted with the EpiQuik TM total histone extraction kit (Epigentek) according to the 
